B-cell-specific surface antigens MS4A1 and CD19 are used as targets in many autoimmune diseases, including MG, with MS4A1 surface molecule (aka CD20) being the most reliable marker of B lymphocytes and CD19 is expressed on a broader group of cells [49]. Here, CD19 is linked to myasthenia gravis.